当前位置： SCI文献检索 > INTERNATIONAL JOURNAL OF CLINICAL PRACTICE期刊下所有文献 > The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.

The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.

Abstract：

AIM:To assess the efficacy and safety of dipeptidyl peptidase 4-inhibitors (DPP4-I) compared with sulphonylureas in adults with type 2 diabetes (T2D) mellitus. METHOD:Randomised controlled trials were collected from PubMed, EMBASE, Google Scholar and conference. The primary outcome was the change in HbA1c. Secondary outcomes included weight gain, the change in postprandial plasma glucose (PPG), insulin resistance and fasting plasma glucose (FPG), adverse event (AE) and incidence of hypoglycaemia. RESULTS:Fourteen studies including 5480 patients randomised to DPP4-I and 5214 patients randomised to sulphonylureas were eligible for the meta-analysis. Compared with sulphonylureas, DPP4-I were associated with a smaller decline in HbA1c (WMD, weighted mean differences 0.08%, 95% CI: 0.03-0.14, p = 0.001), and resulted in weight loss of 1.945 kg (95% CI: -2.237 to -1.653, p < 0.0001). The effect of DPP4-I lowering FPG was inferior to that of sulfonylureas (WMD, 0.268 mmol/l, 95% CI, 0.151-0.385, p < 0.0001), and similar in reducing PPG (WMD, 0.084, 95% CI, -0.701 to 0.869, p = 0.833). According to the follow-up period, the included trials were separated into three groups (group 1: less than half one year, group 2: from half one year to 1 year, group 3: more than 1 year). Subgroup analysis showed that the difference in HbA1c between DPP4-I and sulphonylureas presented a decline curve (group 1: 0.50, 95% CI: 0.15-0.84, group 2: 0.05, 95% CI: -0.05 to 0.15, group 3: 0.09, 95% CI: 0.03-0.15). DPP4-I had a favourable insulin resistance compared with sulfonylureas (WMD, -0.673, 95% CI, -1.248 to -0.097, p = 0.022). In addition, compared with sulfonylureas, DPP4-I was associated with a decrease in overall risk for AE (RR, 0.93, 95% CI, 0.91-0.96, p < 0.0001). The incidence of hypoglycaemia was lower with DPP4-I (RR, 0.24, 95% CI, 0.21-0.27, p < 0.001). CONCLUSION:Patients with T2D who receive DPP4-I could achieve almost similar glycaemic targets with sulphonylureas, with favourable effects on body weight and lower incidence of hypoglycaemia.

journal_name

Int J Clin Pract

journal_title

International journal of clinical practice

authors

Zhou JB,Bai L,Wang Y,Yang JK

doi

10.1111/ijcp.12761

subject

Has Abstract

pub_date

2016-02-01 00:00:00

pages

132-41

issue

eissn

1368-5031

issn

1742-1241

journal_volume

pub_type

杂志文章,meta分析,评审

在线工具

The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.